[1] LI J, XU J G, ZHENG Y D, et al．Esophageal cancer: epidemiology, risk factors and screening [J]．Chin J Cancer Res, 2021, 33(5): 535-547． 

[2] EL-SERAG H B, SWEET S, WINCHESTER C C, et al． Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review [J]．Gut, 2014, 63(6): 871-880． 

[3] TAKAHASHI Y, NAGATA N, SHIMBO T, et al．Long-term trends in esophageal candidiasis prevalence and associated risk factors with or without HIV infection: lessons from an endoscopic study of 80 219 patients [J]．PLoS One, 2015, 10(7): e0133589． 

[4] NAVARRO P, ARIAS Á, ARIAS-GONZÁLEZ L, et al． Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies [J]．Aliment Pharmacol Ther, 2019, 49(9): 1116-1125． 

[5] ZHANG L, RUSSELL D, CONWAY B R, et al．Strategies and therapeutic opportunities for the delivery of drugs to the esophagus [J]．Crit Rev Ther Drug Carrier Syst, 2008, 25(3): 259-304．

[6] 李森林 , 郎翠翠, 付博．新编食管病学[M]．北京: 军 事医学科学出版社, 2011: 4． 

[7] GAVAGHAN M．Anatomy and physiology of the esophagus [J]．AORN J, 1999, 69(2): 372-386． 

[8] ZHANG X C, PATIL D, ODZE R D, et al．The microscopic anatomy of the esophagus including the individual layers, specialized tissues, and unique components and their responses to injury [J]．Ann N Y Acad Sci, 2018, 1434(1): 304-318． 

[9] 孙 进．口服药物吸收与转运[M]．北京: 人民卫生出版社, 2006: 288． 

[10] EMA．JORVEZA® (budesonide) orodispersible tablets 0.5 mg/1.0 mg for oral use: EU prescribing information [EB/ OL]．(2018-01-08)[2024-03-25]．https://www．ema． europa．eu/en/documents/product-information/jorvezaepar- product-information_en.pdf． 

[11] LUCENDO A J, MIEHLKE S, SCHLAG C, et al．Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial [J]．Gastroenterology, 2019, 157(1): 74-86． 

[12] Takeda．EOHILIATM (budesonide) oral suspension 2 mg/10 mL single-dose stick packs for oral use: US prescribing information [EB/OL]．(2024-02-09)[2024-03-25]． https://www．accessdata．fda．gov/drugsatfda_docs/ label/2024/213976s000lbl．pdf． 

[13] DELLON E S, KATZKA D A, COLLINS M H, et al． Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis [J]． Gastroenterology, 2017, 152(4): 776-786． 

[14] HIRANO I, COLLINS M H, KATZKA D A, et al． Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial [J]． Clin Gastroenterol Hepatol, 2022, 20(3): 525-534． 

[15] DI SIMONE M P, BALDI F, VASINA V, et al．Barrier effect of Esoxx® on esophageal mucosal damage: experimental study on ex-vivo swine model [J]．Clin Exp Gastroenterol, 2012, 5: 103-107． 

[16] COLLAUD S, WARLOE T, JORDAN O, et al．Clinical evaluation of bioadhesive hydrogels for topical delivery of hexylaminolevulinate to Barrett’s esophagus [J]．J Control Release, 2007, 123(3): 203-210． 

[17] MAI Y, OUYANG Y, QIN Y J, et al．Poly(lactic acid)- hyperbranched polyglycerol nanoparticles enhance bioadhesive treatment of esophageal disease and reduce systemic drug exposure [J]．Nanoscale, 2022, 14(23): 8418-8428． 

[18] LI X S, ZHAO Y, ZHAO C．Applications of capillary action in drug delivery [J]．iScience, 2021, 24(7): 102810． 

[19] KRAUSE J, ROSENBAUM C, GRIMM M, et al．The EsoCap-system — an innovative platform to drug targeting in the esophagus [J]．J Control Release, 2020, 327: 1-7． 

[20] ITO R, MACHIDA Y, SANNAN T, et al．Magnetic granules: a novel system for specific drug delivery to esophageal mucosa in oral administration [J]．Int J Pharm, 1990, 61(1/2): 109-117． 

[21] CHOI J, HWANG J, KIM J Y, et al．Recent progress in magnetically actuated microrobots for targeted delivery of therapeutic agents [J]．Adv Healthcare Mater, 2021, 10(6): e2001596． 

[22] CHOI H S, JO Y K, AHN G N, et al．Magnetically guidable proteinaceous adhesive microbots for targeted locoregional therapeutics delivery in a highly dynamic environment of esophagus [J]．Adv Funct Mater, 2021, 31(46): 2104602． 

[23] JIN Z, WU K Q, HOU J W, et al．A PTX/nitinol stent combination with temperature-responsive phase-change 1 - h e x a d e c a n o l f o r m a g n e t o c a l o r i c d r u g d e l i v e r y : magnetocaloric drug release and esophagus tissue penetration [J]．Biomaterials, 2018, 153: 49-58． 

[24] SHAIKH M, CHOUDHURY N R, KNOTT R, et al． Engineering stent based delivery system for esophageal cancer using docetaxel [J]．Mol Pharm, 2015, 12(7): 2305- 2317． 

[25] LEE S, HWANG G, KIM T H, et al．On-demand drug release from gold nanoturf for a thermo-and chemotherapeutic esophageal stent [J]．ACS nano, 2018, 12(7): 6756-6766． 

[26] HA D H, CHAE S, LEE J Y, et al．Therapeutic effect of decellularized extracellular matrix-based hydrogel for radiation esophagitis by 3D printed esophageal stent [J]． Biomaterials, 2021, 266: 120477． 

[27] HAGIWARA A, TAKAHASHI T, KITAMURA K, et al． Endoscopic local injection of a new drug delivery formulation, anticancer drug bound to carbon particles, for digestive cancers: pilot study [J]．J Gastroenterol, 1997, 32(2): 141-147． 

[28] DUVALL G A, TARABAR D, SEIDEL R H, et al．Phase 2: a dose-escalation study of OncoGel(ReGel/paclitaxel), a controlled-release formulation of paclitaxel, as adjunctive local therapy to external-beam radiation in patients with inoperable esophageal cancer [J]．Anticancer drugs, 2009,20(2): 89-95． 

[29] DE ARAÚJO J S M, VOLPATO M C, MUNIZ B V, et al． Resistivity technique for the evaluation of the integrity of buccal and esophageal epithelium mucosa for in vitro permeation studies: swine buccal and esophageal mucosa barrier models [J]．Pharmaceutics, 2021, 13(5): 643． 

[30] MAJID H, BARTEL A, BURCKHARDT B B．Development, validation and standardization of oromucosal ex-vivo permeation studies for implementation in quality-controlled environments [J]．J Pharm Biomed Anal, 2021, 194: 113769． 

[31] RICHARDSON J C, DETTMAR P W, HAMPSON F C, et al． Oesophageal bioadhesion of sodium alginate suspensions: 2． suspension behaviour on oesophageal mucosa [J]． Eur J Pharm Sci, 2005, 24(1): 107-114． 

[32] DRUMOND N, STEGEMANN S．Polymer adhesion predictions for oral dosage forms to enhance drug administration safety．Part 2: in vitro approach using mechanical force methods [J]．Colloid Surf B Biointerfaces, 2018, 166: 17-23． 

[33] DO COUTO R O, CUBAYACHI C, CALEFI P L, et al． Combining amino amide salts in mucoadhesive films enhances needle-free buccal anesthesia in adults [J]． J Control Release, 2017, 266: 205-215． 

[34] SMART J D, DUNKLEY S, TSIBOUKLIS J, et al．An in vitro model for the evaluation of the adhesion of solid oral dosage forms to the oesophagus [J]．Int J Pharm, 2013, 447(1/2): 199-203． 

[35] CASIRAGHI A, GENNARI C G, MUSAZZI U M, et al． Mucoadhesive budesonide formulation for the treatment of eosinophilic esophagitis [J]．Pharmaceutics, 2020, 12(3): 211． 

[36] ROSENBAUM C M, BROKMANN F, KRAUSE J, et al． Establishment of a dissolution test system for the biorelevant characterization of esophageal applied dosage forms [J]．J Pharm Sci, 2022, 111(1): 62-68． 

[37] 中国医师协会消化医师分会胃食管反流病专业委员会．中 国高分辨率食管测压临床操作指南( 成人)[J]．中华消化 杂志, 2020, 40(1) : 3-8． 

[38] ZHANG L L, ZHAO W, ZHAO C S, et al．Study on effects of electrical stimulation on rabbit esophageal body motility in vivo [J]．Physiol Res, 2018, 67(2): 275-282． 

[39] KEMPF J, HEINRICH H, REUSCH C E, et al．Evaluation of esophageal high-resolution manometry in awake and sedated dogs [J]．Am J Vet Res, 2013, 74(6): 895-900． 

[40] 胡 琛 , 朱宣进, 黄勇．光学相干断层扫描在胃肠肿瘤 疾病中的应用进展[J]．医学综述, 2018, 24(19): 3888- 3892． 

[41] JELVEHGARAN P, DE BRUIN D M, SALGUERO F J, et al． Feasibility of using optical coherence tomography to detect acute radiation-induced esophageal damage in small animal models [J]．J Biomed Opt, 2018, 23(4): 1-12． 

[42] LI K Y, LIANG W X, MAVADIA-SHUKLA J, et al． Super-achromatic optical coherence tomography capsule for ultrahigh-resolution imaging of esophagus [J]．J Biophotonics, 2019, 12(3): e201800205． 

[43] 高家红, 雷皓 , 陈群 , 等．磁共振成像发展综述[J]． 中国科学: 生命科学, 2020, 50(11): 1285-1295． 

[44] JELVEHGARAN P, STEINBERG J D, KHMELINSKII A, et al．Evaluation of acute esophageal radiation-induced damage using magnetic resonance imaging: a feasibility study in mice [J]．Radiat Oncol, 2019, 14(1): 188． 

[45] LI Y, LIN J M, XIAO J, et al．Therapeutic effects of co-venenum bufonis oral liquid on radiation-induced esophagitis in rats [J]．Exp Anim, 2020, 69(3): 354-362．